Skyrizi Alternatives
Drugs like Skyrizi (risankizumab) — other autoimmune medications advertised on TV that may be alternatives. Informational only — not medical advice. Only your doctor can decide what's right for you.
Unverified catalogue summary (alternative grouping) for Skyrizi in CA; not checked against current local product information.
Humira
adalimumab · AbbVie Corporation
Treats Rheumatoid arthritis, psoriasis, Crohn's disease
Unverified catalogue summary (alternative identity, manufacturer and indication) for Humira in CA; not checked against current local product information.
Dupixent
dupilumab · Sanofi-aventis Canada Inc.
Treats Moderate-to-severe atopic dermatitis, severe type 2/eosinophilic or oral corticosteroid-dependent asthma, severe chronic rhinosinusitis with nasal polyps
Unverified catalogue summary (alternative identity, manufacturer and indication) for Dupixent in CA; not checked against current local product information.
Rinvoq
upadacitinib · AbbVie Corporation
Treats Rheumatoid arthritis, psoriatic arthritis, eczema
Unverified catalogue summary (alternative identity, manufacturer and indication) for Rinvoq in CA; not checked against current local product information.
Sources and editorial standards
Product-label references, not clinical verification. Medicine identification—not prescribing guidance. This page does not provide a complete safety or dosing reference. Check the official label for your country and exact product, and consult your pharmacist or prescriber before starting, stopping or changing treatment. Missing information does not mean a medicine is safe for you. Reference formulation scope (not dosing instructions): Risankizumab SC sterile solution: 150 mg/1 mL, 180 mg/1.2 mL, 360 mg/2.4 mL and 90 mg/1 mL; IV concentrate 600 mg/10 mL for infusion. Crohn's/UC treatment includes IV induction and SC maintenance.
Unresolved / not established by these sources:
- Clinical summaries, safety tiers and dosing guidance are withheld while their review remains unfinished.
- A linked document may have been superseded. Confirm country, product, formulation and latest revision with the regulator or pharmacist.
- CA label reference: Skyrizi — Canadian prescribing monograph (authorized 2026-07-08)
Manufacturer label · Reference scope: Reference link only. Verify the exact formulation and current revision; this does not certify a clinical summary.
- CA regulator product record (not a prescribing label): Health Canada — Summary Basis of Decision
Local licence · Reference scope: Reference link only. Verify the exact formulation and current revision; this does not certify a clinical summary.
Lookup resources (not product-specific citations; confirm formulation and country before use):
Frequently asked questions
What drugs are similar to Skyrizi?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Drugs like Skyrizi include other autoimmune medications advertised on TV such as Humira, Dupixent, Rinvoq. This is an editorial catalogue grouping, not a verified comparison of indications, safety or suitable substitutes. Ask your prescriber about treatment choices.
What can I take instead of Skyrizi?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Other autoimmune medications advertised on TV include Humira, Dupixent, Rinvoq. The right alternative depends on your diagnosis, medical history and insurance — only your doctor can recommend a substitute for Skyrizi. This page is informational only.
Is there a generic version of Skyrizi?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Skyrizi is sold as risankizumab. Whether a lower-cost generic is available depends on patent status — ask your pharmacist, and see the cost & savings page for ways to pay less.
Are these alternatives the same as Skyrizi?
Unverified catalogue grouping, not a clinically established substitute or a checked local indication. This catalogue grouping does not establish therapeutic equivalence, shared approved indications or suitability as a substitute. Do not switch medicines based on it; consult your prescriber.